1. Home /
  2. Biotechnology

Biotechnology

CannTrust Shares Recover After Preliminary Quarterly Loss, New Share Issuance

CannTrust Shares Recover After Preliminary Quarterly Loss, New Share Issuance

Shares of Canadian cannabis-products maker CannTrust drop, then rebound, after the company reveals a preliminary quarterly loss and announces new share issuance.

A Tough Week for Biotech, the Candidates' Whipping Boy Again

A Tough Week for Biotech, the Candidates' Whipping Boy Again

Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.

Amgen: This Beaten Down Blue Chip Is Priced To Own

Amgen: This Beaten Down Blue Chip Is Priced To Own

As the healthcare sector sells off, it's time to look for attractive value. You don't have to go any further than Amgen.

Danaher's Earnings Drop on GE Biopharma Acquisition Costs

Danaher's Earnings Drop on GE Biopharma Acquisition Costs

Danaher reports first-quarter earnings that beat analysts' estimates though revises forward guidance on costs related to acquisition of GE's biopharma business.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

These 2 Biotech Stocks Are No Longer 'Off the Radar'

These 2 Biotech Stocks Are No Longer 'Off the Radar'

Few parts of the market have more volatility than the small caps in this sector.

Johnson & Johnson Rises After Topping First-Quarter Earnings Forecasts

Johnson & Johnson Rises After Topping First-Quarter Earnings Forecasts

Healthcare giant Johnson & Johnson reports first-quarter earnings lower than a year earlier but still above analysts' forecasts.

Catalent to Buy Paragon Bioservices for $1.2 Billion

Catalent to Buy Paragon Bioservices for $1.2 Billion

Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.

Stalking an Entry in Regeneron Pharmaceuticals

Stalking an Entry in Regeneron Pharmaceuticals

A low-risk countertrend options trade may be worth a look in this name.

These 3 Biotech Stocks Are Moving Closer to Profitability

These 3 Biotech Stocks Are Moving Closer to Profitability

Here are updates on small biotech/biopharma names I have profiled before.